TABLE 2.
Distributions of Serum Perfluorochemical Concentrations by Sample and Endometriosis Status (n = 600)
| Operative Sample |
Population Sample |
|||
|---|---|---|---|---|
| Perfluorochemicals Tertiles (ng/ml) |
Endometriosis (n = 190) No. (%)a |
None (n = 283) No. (%)a |
Endometriosis (n = 14) No. (%)a |
None (n = 113) No. (%)a |
| PFOS | ||||
| 1st (0.0300 to 5.3562) | 51 (27) | 105 (37) | 3 (21) | 44 (39) |
| 2nd (5.3563 to 9.2455) | 64 (34) | 99 (35) | 6 (43) | 30 (27) |
| 3rd (9.2456 to 43.2229) | 75 (40) | 79 (28) | 5 (36) | 39 (35) |
| Geometric mean (95% CI) | 7.20 (6.55–7.91) | 6.11 (5.59–6.68) | 7.41 (5.17–10.63) | 6.74 (5.85–7.76) |
| PFOA | ||||
| 1st (−0.3717 to 1.8599) | 49 (26) | 105 (37) | 4 (29) | 45 (40) |
| 2nd (1.8600 to 3.2160) | 67 (35) | 96 (34) | 6 (43) | 30 (27) |
| 3rd (3.2161 to 9.8213) | 74 (39) | 82 (29)a | 4 (29) | 38 (34) |
| Geometric mean (95% CI) | 2.65 (2.44–2.89) | 2.15 (1.96–2.35) | 2.49 (1.82–3.41) | 2.33 (2.04–2.66) |
| PFNA | ||||
| 1st (−0.2100 to 0.5280) | 52 (27) | 110 (39) | 4 (29) | 37 (33) |
| 2nd (0.5281 to 0.8404) | 67 (35) | 91 (32) | 4 (28) | 37 (33) |
| 3rd (0.8405 to 4.0996) | 71 (37) | 82 (29) | 6 (43) | 39 (35) |
| Geometric mean (95% CI) | 0.69 (0.63–0.77) | 0.58 (0.53–0.63) | 0.71 (0.55–0.92) | 0.64 (0.55–0.74) |
| PFDA | ||||
| 1st (−0.0340 to 0.1523) | 51 (27) | 108 (38) | 6 (43) | 38 (34) |
| 2nd (0.1524 to 0.2449) | 65 (34) | 99 (35) | 3 (21) | 31 (27) |
| 3rd (0.2450 to 1.7197) | 74 (39) | 76 (27) | 5 (36) | 44 (39) |
| Geometric mean (95% CI) | 0.20 (0.18–0.22) | 0.18 (0.16–0.19) | 0.17 (0.13–0.22) | 0.19 (0.16–0.22) |
| PFHxS | ||||
| 1st (0.0026 to 0.3277) | 54 (28) | 110 (39) | 3 (21) | 36 (32) |
| 2nd (0.3278 to 0.6071) | 70 (37) | 86 (30) | 5 (36) | 38 (34) |
| 3rd (0.6072 to 17.1021) | 66 (35) | 87 (31) | 6 (43) | 39 (35) |
| Geometric mean (95% CI) | 0.48 (0.43–0.54) | 0.43 (0.39–0.47) | 0.59 (0.37–0.96) | 0.51 (0.44–0.60) |
| PFHpA | ||||
| 1st (0.0000 to 0.0307) | 65 (34) | 79 (28) | 6 (43) | 53 (47) |
| 2nd (0.0308 to 0.0951) | 56 (30) | 102 (36) | 4 (29) | 36 (32) |
| 3rd (0.0952 to 1.4994) | 69 (36) | 102 (36) | 4 (29) | 23 (21) |
| Geometric mean (95% CI) | 0.05 (0.04–0.06) | 0.05 (0.05–0.06) | 0.03 (0.01–0.08) | 0.03 (0.02–0.04) |
| PFUnDA | ||||
| 1st (0.0001 to 0.0347) | 54 (28) | 94 (33) | 7 (50) | 48 (43) |
| 2nd (0.0348 to 0.1199) | 67 (35) | 100 (35) | 3 (21) | 29 (26) |
| 3rd (0.1200 to 1.5453) | 69 (36) | 89 (31) | 4 (29) | 36 (32) |
| Geometric mean (95% CI) | 0.06 (0.05–0.08) | 0.05 (0.05–0.06) | 0.03 (0.01–0.08) | 0.05 (0.04–0.06) |
| PFDoDA | ||||
| 1st (0.0000 to 0.0173) | 56 (30) | 101 (36) | 3 (21) | 42 (38) |
| 2nd (0.0174 to 0.0342) | 72 (38) | 94 (33) | 5 (36) | 28 (25) |
| 3rd (0.0343 to 0.2338) | 62 (33) | 88 (31) | 6 (43) | 42 (38) |
| Geometric mean (95% CI) | 0.02 (0.02–0.03) | 0.02 (0.02–0.02) | 0.03 (0.01–0.04) | 0.02 (0.02–0.03) |
| PFOSA | ||||
| 1st (0.0000 to 0.0146) | 57 (30) | 95 (34) | 3 (21) | 48 (43) |
| 2nd (0.0147 to 0.0311) | 75 (40) | 94 (33) | 3 (21) | 26 (23) |
| 3rd (0.0312 to 0.0900) | 58 (31) | 94 (33) | 8 (57) | 38 (34) |
| Geometric mean (95% CI) | 0.02 (0.02–0.02) | 0.02 (0.02–0.02) | 0.03 (0.02–0.04) | 0.02 (0.01–0.02) |
PFUnDA indicates perfluoroundecanoic acid.
Excludes 26 women with missing diagnostic information: 22 women in the operative sample whose surgeries were canceled and 4 women whose MRIs were unreadable for diagnostic purposes.
a
No. (%), except where indicated.